Loading…
This event has ended. View the official site or create your own event → Check it out
This event has ended. Create your own
View analytic
Friday, November 27 • 7:45am - 8:10am
Breakfast Session- Economic Impact of Innovative Financing Models

Log in to save this to your schedule and see who's attending!

 Organized by Eli Lilly

The field of venture-backed investments into early-stage (preclinical to Phase 2a) biopharmaceuticals has seen a shift to a greater reliance on virtual models of drug development.  This trend is based on the fact that expertise required for drug discovery and preclinical drug development differs in large part from that required for clinical development.  Building R&D teams de novo for each asset can result in “feast and famine” for the local economies where teams of experts are hired, to be let go once the product moves along the drug development continuum.  The virtual model of drug development provides for a more stable employment environment as it looks to engage the “best and brightest” from established companies and independent consultants to fill the resources required to take a product through the series of developmental hurdles.  As well as “feeding” the local established economy, the model bolsters strong local capabilities by also sourcing internationally top key opinion leaders and established groups with long records of drug development.  This model results in greater capital and timeline efficiencies, an increased likelihood of investing in “winners” and a process for drug development focused on getting innovative therapies to patients as quickly as possible. 

Our esteemed panel of experts all contribute to this ecosystem;

  • Organizations like FACIT, work with academic groups to identify innovative medicines of highest interest and provide a link to the key opinion leaders in a specific field.
  • Investors like Teralys who invest both directly and indirectly into the model of virtual drug development; supporting the local and international ecosystems of expert drug developers.
  • Venture Capital teams, like TVM Capital, who understand the value of team building in later-stage companies and have applied the virtual model of drug development at early stages in order to support the ecosystem of service providers, academic key opinion leaders and expert consultants in Canada and internationally. 

Moderators
avatar for Cynthia Lavoie

Cynthia Lavoie

General Partner, TVM Capital Life Science
Dr. Lavoie is a General Partner with TVM Capital Life Science, an international venture capital firm with more than $1 billion under management. Dr. Lavoie is responsible for deal making, deal origination and execution and for the management of portfolio companies in the US and Canada. Dr. Lavoie has led investments into Montreal-based TVM companies Kaneq Bioscience and FAAH Pharma, where she serves on the Boards of Directors. Dr. Lavoie also... Read More →

Speakers
avatar for Cedric Bisson

Cedric Bisson

Partner, Teralys Capital
CEDRIC BISSON is partner at Teralys Capital, Canada’s largest technology fund of funds management organization, where he focuses on healthcare and life sciences investments. He has spent the past two decades across Canada, in Europe and the USA creating, building and advising innovative businesses, serving as founder and partner of iNovia Capital (a leading pan-Canadian VC firm), founder of MSBi Valorisation (now Aligo, seed technology... Read More →
avatar for Daniel Bouthillier

Daniel Bouthillier

President and CEO, Kaneq Pharma
Daniel Bouthillier possède plus de 25 ans d’expérience en administration de la recherche. Il est présentement Président et chef de la direction de Kaneq Pharma. Auparavant il a occupé différents postes chez Merck&Co où il fut Directeur exécutif à l’Administration et à la planification de la recherche pour différents centres de recherche... Read More →
avatar for Jeff Courtney

Jeff Courtney

Chief Commercial Officer, Fight Against Cancer Innovation Trust (FACIT), Ontario Institute for Cancer Research (OICR)
Mr. Jeff Courtney was appointed Chief Commercial Officer of the Fight Against Cancer Innovation Trust (FACIT), the commercialization partner for the Ontario Institute for Cancer Research (OICR) in November 2012. He is leading the Institute’s efforts to commercialize novel approaches to the diagnosis and treatment of cancer resulting from research conducted in Ontario. Mr. Courtney has extensive experience in venture capital, business... Read More →
avatar for Dr. Marc Rivière

Dr. Marc Rivière

General Partner, TVM Capital
Marc Rivière joined the Montreal-based TVM Capital Life Science team in 2013 after twenty years of international drug development preceded by ten years of medical and public health practice in Europe and the Middle East. Marc’s expertise encompasses all aspects of drug development in different clinical indications from pre-clinical development to post marketing surveillance. At TVM Capital Life Science, he focuses on evaluation of... Read More →


Friday November 27, 2015 7:45am - 8:10am
Ballroom A/B (ground floor)

Attendees (22)




Twitter Feed